Rocket
Premium
Excel Add-In
International
Tools
Dashboard
Screener
Spinoffs
IPOs
Register
Alerts
Sign In
Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
1-A
1-A POS
1-A-W
1-A/A
1-K
1-K/A
1-SA
1-SA/A
1-U
1-U/A
1-Z
1-Z-W
1-Z/A
1/A
10-12B
10-12B/A
10-12G
10-12G/A
10-D
10-D/A
10-K
10-K/A
10-K405
10-K405/A
10-KT
10-KT/A
10-Q
10-Q/A
10-QSB
10-QSB/A
10-QT
10-QT/A
10KSB
11-K
11-K/A
11-KT
13F-HR
13F-HR/A
13F-NT
13F-NT/A
13FCONP
144
144/A
15-12B
15-12B/A
15-12G
15-12G/A
15-15D
15-15D/A
15F-12B
15F-12G
15F-12G/A
15F-15D
18-K
18-K/A
19B-4E
2-E
20-F
20-F/A
20FR12B
20FR12B/A
20FR12G/A
24F-2NT
24F-2NT/A
25
25-NSE
25-NSE/A
25/A
253G1
253G2
253G3
3
3/A
305B2
305B2/A
4
4/A
40-17F1
40-17F1/A
40-17F2
40-17F2/A
40-17G
40-17G/A
40-202A
40-202A/A
40-206A
40-24B2
40-33
40-6B
40-6B/A
40-6C
40-6C/A
40-8B25
40-8F-2/A
40-APP
40-APP/A
40-F
40-F/A
40-OIP
40-OIP/A
40FR12B
40FR12B/A
424B1
424B2
424B3
424B4
424B5
424B7
424B8
424H
424H/A
425
485APOS
485B24E
485BPOS
485BXT
486APOS
486BPOS
486BXT
487
497
497AD
497J
497K
5
5/A
6-K
6-K/A
8-A12B
8-A12B/A
8-A12G
8-A12G/A
8-K
8-K/A
8-K12B
8-K12B/A
8-K12G3
8-K12G3/A
8-K15D5
8-K15D5/A
8-M
9-M
ABS-15G
ABS-15G/A
ABS-EE
ABS-EE/A
ADV-E
ADV-H-C
ADV-H-T
ADV-NR
ANNLRPT
APP NTC
APP ORDR
APP WD
APP WD/A
ARS
ARS/A
ATS-N
ATS-N/CA
ATS-N/MA
ATS-N/UA
AW
AW WD
C
C-AR
C-AR-W
C-AR/A
C-TR
C-U
C-U-W
C-W
C/A
C/A-W
CB
CB/A
CERT
CERTARCA
CERTBATS
CERTCBO
CERTNAS
CERTNYS
CERTPAC
CFPORTAL
CFPORTAL/A
CORRESP
CT ORDER
D
D/A
DEF 14A
DEF 14C
DEF13E3
DEF13E3/A
DEFA14A
DEFA14C
DEFC14A
DEFC14A
DEFC14C
DEFM14A
DEFM14C
DEFN14A
DEFR14A
DEFR14C
DEFS14A
DEFS14C
DEL AM
DFAN14A
DFRN14A
DOS/A
DSTRBRPT
DSTRBRPT/A
EFFECT
F-1
F-1/A
F-10
F-10/A
F-10EF
F-1MEF
F-3
F-3/A
F-3ASR
F-3D
F-4
F-4/A
F-6
F-6 POS
F-6/A
F-6EF
F-7
F-8 POS
F-80
F-N
F-X
F-X/A
FOCUSN
FOCUSN/A
FWP
G-405
G-FIN/A
IRANNOTICE
MA
MA-A
MA-I
MA-I/A
MA-W
MA/A
MSD
MSD/A
N-14
N-14 8C
N-14 8C/A
N-14/A
N-14MEF
N-18F1
N-1A
N-1A/A
N-2
N-2/A
N-23C-2
N-23C3A
N-23C3B
N-2MEF
N-30B-2
N-30D
N-30D/A
N-4
N-4/A
N-54A
N-54C
N-6
N-6/A
N-6F
N-8A
N-8A/A
N-8B-2/A
N-8F
N-8F NTC
N-8F ORDR
N-8F/A
N-CEN
N-CEN/A
N-CSR
N-CSR/A
N-CSRS
N-CSRS/A
N-MFP2
N-MFP2/A
N-PX
N-PX/A
N-Q
N-Q/A
NO ACT
NPORT-P
NPORT-P/A
NRSRO-CE
NRSRO-CE/A
NRSRO-UPD
NSAR-A
NSAR-A/A
NSAR-AT
NSAR-B
NSAR-B/A
NSAR-BT
NSAR-U
NSAR-U/A
NT 10-K
NT 10-K/A
NT 10-Q
NT 10-Q/A
NT 11-K
NT 20-F
NT 20-F/A
NT N-CEN
NT N-MFP2
NT NPORT-EX
NT-NCSR
NT-NCSR/A
NT-NSAR
NT-NSAR/A
NTFNCSR
NTN 10Q
POS 8C
POS AM
POS AMI
POS EX
POS462B
POSASR
PRE 14A
PRE 14C
PREC14A
PREC14C
PREM14A
PREM14C
PREN14A
PRER14A
PRER14C
PRRN14A
PX14A6G
QRTLYRPT
QUALIF
REG-NR
REGDEX
REGDEX/A
REVOKED
RW
RW WD
S-1
S-1/A
S-11
S-11/A
S-11MEF
S-1MEF
S-1MEF
S-3
S-3/A
S-3ASR
S-3D
S-3DPOS
S-3MEF
S-4
S-4 POS
S-4/A
S-4MEF
S-6
S-6/A
S-8
S-8 POS
S-B
S-B/A
SC 13D
SC 13D/A
SC 13E
SC 13E/A
SC 13E1
SC 13E1/A
SC 13E3
SC 13E3/A
SC 13E4
SC 13E4/A
SC 13G
SC 13G/A
SC 14D9
SC 14D9/A
SC 14F1
SC TO-C
SC TO-I
SC TO-I/A
SC TO-T
SC TO-T/A
SC14D9C
SD
SD/A
SDR/A
SE
SEC STAFF
SEC STAFF ACTION
SEC STAFF LETTER
SF-1/A
SF-3
SF-3/A
SUPPL
T-3
T-3/A
TA-1
TA-1/A
TA-2
TA-2/A
TA-W
UPLOAD
WDL-REQ
X-17A-5
X-17A-5/A
Tags
Director departure
Appointed director
Quarterly results
22nd Century Group, Inc. (XXII)
Create:
Alert
All
|
News
|
Filings
Date Filed
Type
Description
04/29/2021
GN
Congresswoman Gwen Moore Adds Voice to Groundswell of Support for Reducing Nicotine in Cigarettes, Encourages HHS Secretary Becerra to Take Action to Save Lives and End Health Disparities
04/26/2021
GN
22nd Century Delivers 3.6 Million Variable Nicotine Content Research Cigarettes for Independent Scientific Studies
04/22/2021
GN
22nd Century Group to Host Webcast to Discuss First Quarter 2021 Results
04/21/2021
GN
22nd Century Group Issues Annual Letter to Shareholders
04/08/2021
GN
22nd Century Group Regulatory Science VP Joins FDLI Tobacco and Nicotine Products Committee
04/01/2021
GN
Multiple Former FDA Commissioners Voice Support for Reduced Nicotine Mandate; Proposed Legislation Would Be Game-Changing for 22nd Century
03/19/2021
GN
Becerra Confirmation Boosts 22nd Century's Position to Disrupt Tobacco Industry
03/12/2021
GN
22nd Century Group Receives Additional $3.7 Million from Cash Exercise of Outstanding Warrants
03/05/2021
GN
22nd Century Group to Participate in Investor Conferences in March 2021
03/04/2021
GN
22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants
03/03/2021
GN
22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and Intellectual Property
02/25/2021
GN
22nd Century Group to Host Webcast to Discuss Fourth Quarter and Full-Year 2020 Results
02/24/2021
GN
22nd Century Group Provides Business Update Letter from CEO
02/10/2021
GN
22nd Century Group and KeyGene Launch Advanced Cannabis Technology Platform for Accelerated Development of New Varieties of Hemp/Cannabis Plants with Commercially Valuable Traits
01/28/2021
GN
22nd Century Group to Relocate Headquarters to Buffalo's Thriving Larkinville District
01/26/2021
GN
The Buffalo News Op-ed: 22nd Century CEO Urges FDA to Proceed with Plan to Limit Nicotine Levels in Cigarettes
01/19/2021
GN
Federal Court Dismisses Securities Class Action Lawsuit Against 22nd Century Group
01/12/2021
GN
22nd Century Group??VLN®??????????????????????????
01/12/2021
GN
22nd Century Group ?? VLN® ??????,???????????????????????
01/12/2021
GN
22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company's Reduced Nicotine Content Cigarettes
01/11/2021
GN
22nd Century Group Expands VLN® Tobacco Growing Program to Support Anticipated Demand of the Company's Reduced Nicotine Content Cigarettes
12/17/2020
GN
22nd Century Group Achieves Breakthrough Hemp/Cannabis GMO Technology; Granted New Patent for Controlling Genes Responsible for Production of CBD, THC, and Other Valuable Cannabinoids
12/08/2020
GN
22nd Century Receives Order for 3.6 Million New SPECTRUM® Variable Nicotine Cigarettes for U.S. Government-Supported Research
11/24/2020
GN
22nd Century's Vice President of Regulatory Science Publishes Important Public Policy Article
11/18/2020
GN
22nd Century Group CEO James A. Mish to Speak at Cowen 2020 Boston Cannabis Conference
11/16/2020
GN
22nd Century Group to Present at the Virtual Fall Investor Summit on November 17
10/22/2020
GN
22nd Century Group to Host Third Quarter 2020 Webcast and Conduct Quarterly Q&A
10/19/2020
GN
22nd Century Group to Highlight its Reduced Nicotine Technology at The Food and Drug Law Institute's Tobacco and Nicotine Products Regulation and Policy Conference
10/14/2020
GN
22nd Century Group Achieves Breakthrough Technology; Granted New Patent for Reducing Nicotine in Tobacco Plants
09/24/2020
GN
22nd Century Group Provides Strategy Update Letter from CEO
09/17/2020
GN
22nd Century Appoints Leading Plant Biotechnology Expert Dr. Michael Koganov to Board of Directors
08/27/2020
GN
22nd Century Group to Present at the LD Micro 500 Virtual Conference
08/06/2020
GN
22nd Century Group Reports Financial Results and Business Highlights for the Second Quarter 2020
06/03/2020
GN
22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer
Next >>
Rocket Data Systems, Inc. © 2019 |
Contact Us
|
Data Disclaimer
|
Terms of Use
|
Privacy